Laura Hovind

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Kelly E. Dooley, Susan L. Rosenkranz, Francesca Conradie et al. · The Lancet Infectious Diseases · 2021 · 117 citations · Full text

Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis, Pharmacology +8

Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1–infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275)

Daniel E. Nixon, Ronald J. Bosch, Ellen S. Chan et al. · Journal of clinical lipidology · 2016 · 36 citations · Full text

Inflammation, Metabolic Syndrome, Cardiovascular Disease +13

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

Beatriz Grinsztejn, Michael D. Hughes, Justin Ritz et al. · The Lancet HIV · 2019 · 36 citations · Full text

Sexual Health, Epidemiology, Actg A5288 +9

Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy

Rajesh T. Gandhi, Ronald J. Bosch, Hanna Mar et al. · The Journal of Infectious Diseases · 2023 · 28 citations · Full text

A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome

Carlos A. M. Silva, Barbara Graham, Kristofor J. Webb et al. · International Journal of Infectious Diseases · 2019 · 26 citations · Full text